Charles River Laboratories Presents Robust Program at Neuroscience 2016
11 November 2016 - 12:00AM
Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that its team of leading Central Nervous System (CNS) and
neurological disease experts is presenting 25 scientific posters
and one podium presentation, both independently and collaboratively
with clients, at Neuroscience 2016, the annual meeting of the
Society for Neuroscience (SfN). The meeting, which brings
together over 30,000 researchers from more than 80 countries, is
taking place from November 12-16 in San Diego, California.
“The field of neuroscience is rapidly changing and evolving,”
said Patrick Sweeney, Managing Director of Charles River Discovery
Services. “At this year’s conference, we will host two scientific
discussions on the development of therapeutics for aging and the in
vitro and in vivo aspects of drug discovery. We see Neuroscience
2016 as an important opportunity for our experts to collaborate
with top scientists from across the globe, sharing our scientific
expertise and learning from colleagues.”
Among the posters the Charles River team will present are
innovative tools and applications for research targeting
Huntington’s, Alzheimer’s, Parkinson’s, Multiple Sclerosis,
Duchenne Muscular Dystrophy, and other neurological disorders.
Noteworthy examples include:
- A collaboration with the University of
Eastern Finland and Kuopio University Hospital on the use of
dynamic PET imaging. (Dynamic PET Imaging with Arterial Input
Function of Lipopolysaccharide-Induced Neuroinflammation in
Rat)
- A collaboration with Cure Huntington's
Disease Initiative (CHDI) on the utilization of Rho kinase
inhibitors for Huntington’s disease therapeutics. (Progress Towards
Potent, Selective and Brain Penetrant Rho Kinase Inhibitors
Suitable for a Proof-of-Concept Study in HD Models)
- The study of altered nerve cell
function in Huntington’s disease models. (Investigation of
Corticostriatal Synaptic Transmission and Cerebellar Purkinje
Neuron Firing in the R6/2 Mouse Model of Huntington’s Disease by
Using Multi-Electrode Arrays)
Additionally, the Charles River team, in conjunction with Sage
Therapeutics, will participate in a nanosymposium titled “Epilepsy:
Mechanisms” to discuss an optimized high-throughput screening
approach to identify positive allosteric modulators of
N-methyl-D-aspartate glutamate receptors (NMDARs), which are
promising therapeutic targets for numerous neurological
indications. This symposium will be held on Monday, November 14,
2016. Nikolai Fedorov, Principal Scientist, Discovery Screening
Services at Charles River, will present at 10:00am PST. As a part
of its continued focus on high-throughput screening as a mechanism
for studying CNS, Charles River recently expanded its ion channel
capabilities through the addition of a Sophion Qube 384-well
automated patch-clamp platform.
A full schedule of Charles River’s activities during
Neuroscience 2016 is available on our website, and reprints of each
poster are available in Charles River’s booth (#1619) during the
conference. Additionally, CNS experts are available for meetings
with those interested in discussing neuroscience research and drug
discovery. Throughout the conference, Charles River will be
providing live updates on the Eureka Blog, including reviews
of scientific sessions and input on the research being
presented.
About the Society for Neuroscience
The Society for Neuroscience is the world’s largest
organization of scientists and physicians devoted to understanding
the brain and nervous system. The nonprofit organization, founded
in 1969, now has nearly 40,000 members in more than 90 countries
and 130 chapters worldwide.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161110005170/en/
Media Contact:Charles River Laboratories
International, Inc.Amy Cianciaruso, 781-222-6168Corporate Vice
President, Public Relationsamy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2024 to May 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From May 2023 to May 2024